Represents the amount of milestone payments the Company is entitled to receive based on the terms of the agreement.

No definition available.

Name:	pcrx_CollaborativeArrangementMilestonePaymentsToBeReceivedMaximum
Namespace Prefix:	pcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Contractual Obligation, Minimum Monthly Commission, Duration

+ References

No definition available.

+ Details

Name:	pcrx_ContractualObligationMinimumMonthlyCommissionDuration
Namespace Prefix:	pcrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Contractual Obligation, Mutual Termination Rights Term

+ References

No definition available.

+ Details

Name:	pcrx_ContractualObligationMutualTerminationRightsTerm
Namespace Prefix:	pcrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Litigation Settlement, Amount Expected To Be Awarded from Other Party

+ References

No definition available.

+ Details

Name:	pcrx_LitigationSettlementAmountExpectedToBeAwardedFromOtherParty
Namespace Prefix:	pcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Litigation Settlement, Volume-Limited, Increase Period

+ References

No definition available.

+ Details

Name:	pcrx_LitigationSettlementVolumeLimitedIncreasePeriod
Namespace Prefix:	pcrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

- Definition

Litigation Settlement, Volume-Limited, Maximum Percentage, Period

+ References

No definition available.

+ Details

Name:	pcrx_LitigationSettlementVolumeLimitedMaximumPercentagePeriod
Namespace Prefix:	pcrx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

- Definition

Litigation Settlement, Volume-Limited, Number Of Moderate Increase Periods

+ References

No definition available.

+ Details

Name:	pcrx_LitigationSettlementVolumeLimitedNumberOfModerateIncreasePeriods
Namespace Prefix:	pcrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number Of Generic Drug Manufacturers

+ References

No definition available.

+ Details

Name:	pcrx_NumberOfGenericDrugManufacturers
Namespace Prefix:	pcrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Paragraph IV Certifications

+ References

No definition available.

+ Details

Name:	pcrx_NumberOfParagraphIVCertifications
Namespace Prefix:	pcrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue from Contract with Customer, Milestone Payments, Maximum

+ References

No definition available.

+ Details

Name:	pcrx_RevenueFromContractWithCustomerMilestonePaymentsMaximum
Namespace Prefix:	pcrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage of voting equity interest acquired in business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-38

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

+ Details

Name:	us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-11

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-2

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount awarded from other party in judgment or settlement of litigation.

+ References

No definition available.

+ Details

Name:	us-gaap_LitigationSettlementAmountAwardedFromOtherParty
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Interest expense (income) directly attributable to an award in settlement of litigation.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(6))
-SubTopic 10
-Topic 220
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_LitigationSettlementInterest
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of loss from litigation settlement for amount awarded to other party. Excludes claims within an insurance entity's normal claims settlement process.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-1

+ Details

Name:	us-gaap_LitigationSettlementLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482645/405-30-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.W.Q2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479583/944-40-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 720
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483359/720-20-50-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 27
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482395/460-10-55-27

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482425/460-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-1

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The total number of new claims filed pertaining to a loss contingency during the period.

+ References

+ Details

Name:	us-gaap_LossContingencyNewClaimsFiledNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of pending claims pertaining to a loss contingency.

+ References

+ Details

Name:	us-gaap_LossContingencyPendingClaimsNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Cash received for the settlement of litigation during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

+ Details

Name:	us-gaap_ProceedsFromLegalSettlements
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=pcrx_GQBioTherapeuticsGmbHMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=pcrx_GQBioTherapeuticsGmbHMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=pcrx_JohnsonJohnsonMedTechMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=pcrx_ZILRETTAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=pcrx_GeneQuineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	pcrx_AchievementOfMilestoneAxis=pcrx_AchievementOfDevelopmentAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=pcrx_FlexionTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	pcrx_AchievementOfMilestoneAxis=pcrx_InitiationOfAPhase2ClinicalTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	pcrx_AchievementOfMilestoneAxis=pcrx_DevelopmentAndGlobalRegulatoryApprovalMilestonePaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=pcrx_BaylorCollegeOfMedicineBaylorMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=pcrx_LGChemPartnershipAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=pcrx_AmacaTheraIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pcrx_MyoScienceMilestoneLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pcrx_ResearchDevelopmentFoundationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

COMMITMENTS AND CONTINGENCIES (Details) $ in Thousands		1 Months Ended				3 Months Ended		9 Months Ended		12 Months Ended
COMMITMENTS AND CONTINGENCIES (Details) $ in Thousands	Nov. 02, 2026 law_suit	Oct. 31, 2025 manufacturer certificate	Jul. 31, 2025	Jun. 30, 2025 USD ($)	Mar. 31, 2025 USD ($)	Sep. 30, 2026 USD ($)	Sep. 30, 2025 USD ($) notice	Sep. 30, 2026 USD ($)	Sep. 30, 2025 USD ($) notice	Dec. 31, 2025 USD ($)	Dec. 31, 2017 USD ($)	Jan. 31, 2026 USD ($)	Apr. 07, 2025 period	Feb. 28, 2025	Aug. 31, 2023 USD ($)
Loss Contingencies [Line Items]
Volumes distributed in US market in duration period													12 months
Increasing modestly period \| period													2
Agreement period of volumes distributed in market													3 years
Legal settlement						$ 0	$ 0	$ 0	$ 7,000
Number of paragraph certification \| certificate		2
Number of generic drug manufacturers \| manufacturer		2
Upfront payment						2,000		2,000
Research and development						$ 26,682	25,966	$ 84,997	79,859
Subsequent Event
Loss Contingencies [Line Items]
Number of filed complaints \| law_suit	2
GQ Bio Therapeutics GmbH
Loss Contingencies [Line Items]
Percentage of voting interests acquired														81.00%
GQ Bio Therapeutics GmbH \| GQ Bio Therapeutics GmbH
Loss Contingencies [Line Items]
Percentage of voting interests acquired														81.00%
Johnson & Johnson MedTech
Loss Contingencies [Line Items]
Mutual termination rights term			1 year
Johnson & Johnson MedTech \| ZILRETTA
Loss Contingencies [Line Items]
Option extended term			12 months
GeneQuine \| Achievement of Development and Regulatory Milestones \| Flexion
Loss Contingencies [Line Items]
Achievement of commercial milestones (up to)											$ 56,000
GeneQuine \| Initiation of a Phase 2 Clinical Trial \| Flexion
Loss Contingencies [Line Items]
Achievement of commercial milestones (up to)											4,500
GeneQuine \| Development and Global Regulatory Approval Milestone Payments \| Flexion
Loss Contingencies [Line Items]
Achievement of commercial milestones (up to)											51,500
Baylor College of Medicine (Baylor) \| Minimum
Loss Contingencies [Line Items]
Range of milestone payment											100
Baylor College of Medicine (Baylor) \| Maximum
Loss Contingencies [Line Items]
Range of milestone payment											$ 600
LG Chem, Partnership Agreement
Loss Contingencies [Line Items]
Upfront payment												$ 2,000
AmacaThera, Inc
Loss Contingencies [Line Items]
Research and development										$ 5,000
MyoScience Milestone Litigation
Loss Contingencies [Line Items]
Repayments for royalties					$ 5,200				5,200
Research Development Foundation
Loss Contingencies [Line Items]
Repayments for royalties				$ 23,100			23,100		$ 23,100
Expect to receive partial summary judgment															$ 23,100
Additional interest payments				$ 5,200			5,200
Payment received							$ 28,300
Number of notices are filed \| notice							2		2